Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers

Video

Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discussesthe results from a phase I trialinvestigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.

Recent Videos